
Deighan brings more than two decades of financial leadership experience to the role
Whippany, NJ, November 19, 2026 – Woodstock Sterile Solutions, a leading blow-fill-seal (BFS) contract development and manufacturing organization (CDMO), and Halo Pharma, a leading CDMO providing drug product development, clinical, and commercial manufacturing services, have announced that pharmaceutical industry veteran John Deighan is now serving as the Chief Financial Officer for both organizations.
Deighan has more than 20 years of finance leadership experience across pharmaceutical, generic, and consumer health businesses. His expertise includes prior CFO experience, including pharmaceutical multi-site manufacturing businesses, contract manufacturing, financial planning and forecasting, capital raising, and mergers and acquisitions.
“John’s experience in pharmaceutical drug product development and manufacturing will broaden our already experienced team that will shape Halo and Woodstock as we look to grow our CDMO partnerships. John’s background in working with operating companies, including working in companies that develop and produce sterile products, is particularly important as we now will have Halo NJ as well as Woodstock both producing sterile products,” said Lee Karras, Group CEO of Woodstock Sterile Solutions and Halo Pharma. “His combination of pharmaceutical finance and manufacturing expertise will be a valuable addition as we continue building Halo and Woodstock into market leaders.”
“Halo Pharma and Woodstock Sterile Solutions have established strong positions in the pharmaceutical manufacturing industry. I look forward to working with Lee and the leadership team to deliver strong financial performance, support disciplined growth, and align our financial strategies and resources with opportunities to create long-term value,” said Deighan.
For more information about Woodstock Sterile Solutions, visit https://woodstocksterilesolutions.com and for information on Halo Pharma, visit https://halopharma.com.
About Halo Pharma
Halo Pharma is a rapidly growing contract development and manufacturing organization (CDMO) that provides scientific and development expertise, as well as a wide spectrum of manufacturing services, from its locations in Whippany, New Jersey, USA and Montreal, Quebec, Canada to its international client base. Halo offers fully integrated capabilities in a variety of dosage forms including tablets, capsules, powders, liquids, creams, sterile and non-sterile ointments and suppositories. The company is registered to work with any of these dosages in the CI-CV DEA designations. Halo Pharma’s capabilities in the areas of tech transfer, process and product development, production, scale-up/validation and analytical method development allow us to partner with clients from development through commercialization or at any point along the way. For more information, please contact [email protected].
About Woodstock Sterile Solutions
For more than 55 years, Woodstock Sterile Solutions has been recognized as a leading Blow-Fill-Seal (BFS) Contract Development and Manufacturing Organization (CDMO). We develop and supply BFS products for pharmaceutical and healthcare companies, providing best-in-class sterile development manufacturing solutions across a broad – and growing – range of applications, including diagnostic, respiratory, ophthalmic, topical, otic, and oral. As a highly focused organization, our expertise and commitment to innovation allow us to reduce development times and efficiently support our customers’ ability to deliver products to market. At Woodstock Sterile Solutions, we see a patient, family member or friend in every product we make, and our goal is to be the best development and commercial partner in the industry, delivering life-enhancing molecules from the benchtop to the patient.
Media Contact
Resource Advantage
Dan Green
[email protected]
Company Contact
Woodstock Sterile Solutions/Halo Pharma
Stacy London
[email protected]